Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JANUMET vs BUTORPHANOL TARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Management of moderate to severe pain,Preoperative medication,Supplement to balanced anesthesia,Relief of pain during labor,Off-label: Migraine headache (via intranasal route)
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Sitagliptin is primarily excreted unchanged in urine via active tubular secretion, with minor metabolism via CYP3A4 and CYP2C8. Metformin is not metabolized and is excreted unchanged in urine by tubular secretion.
Butorphanol is extensively metabolized in the liver via hydroxylation and N-dealkylation, primarily by CYP3A4. The major metabolite is hydroxybutorphanol, which has some analgesic activity but is less potent.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Sitagliptin: 38% (albumin). Metformin: negligible (<5%).
Approximately 80% bound to plasma proteins (mainly alpha-1-acid glycoprotein and albumin).
Sitagliptin: 198 L (≈2.8 L/kg for 70 kg). Metformin: 654 L (≈9.3 L/kg for 70 kg). Clinical meaning: Metformin Vd indicates extensive tissue distribution, predominantly in gastrointestinal tissues and red blood cells.
Vd: 4-5 L/kg (range 3-6 L/kg), indicating extensive tissue distribution, including CNS.
Sitagliptin: 87% (oral). Metformin: 50-60% (oral), variable with food.
Intranasal: 60-70% (range 48-80%); IM: 80-100% (complete but variable); Oral: very low (<5%) due to extensive first-pass metabolism; not used orally.
Contraindicated if e GFR <30 m L/min/1.73 m2. e GFR 30-45: do not initiate; if already on therapy, reduce dose to 25 mg sitagliptin/500 mg metformin once daily. e GFR 45-60: maximum dose 50 mg sitagliptin/1000 mg metformin twice daily. Monitor renal function.
No specific guidelines for dose adjustment in renal impairment; use with caution. For severe renal impairment (e GFR <30 m L/min), consider reducing dose and/or extending dosing interval due to potential accumulation of active metabolites.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component risk of lactic acidosis.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50% and monitor for excessive sedation. Class C: Avoid use or reduce dose to 25% of normal and monitor closely.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Weight-based: 0.01-0.02 mg/kg intravenously or intramuscularly every 3-4 hours as needed; maximum single dose 1 mg. For intranasal: 1 mg as a single dose in patients ≥18 kg (for migraine). Not recommended for PCA in children.
Use with caution; monitor renal function closely. Initiate at lowest dose (25 mg sitagliptin/500 mg metformin) and titrate slowly. Avoid in patients aged ≥80 years unless normal renal function confirmed.
Reduce initial dose by 50% (e.g., 0.5-1 mg IV/IM every 4-6 hours); titrate cautiously due to increased sensitivity to opioid effects and risk of respiratory depression. For intranasal, consider lower dose (0.5 mg). Monitor renal function.
Lactic acidosis: Metformin hydrochloride can cause lactic acidosis, a rare but serious condition. If suspected, discontinue Janumet and treat promptly.
Concomitant use of opioids with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Lactic acidosis risk (sepsis, dehydration, hepatic impairment, alcohol abuse, unstable CHF, radiologic contrast studies),Pancreatitis (discontinue if suspected),Hypoglycemia (especially with sulfonylurea or insulin coadministration),Renal impairment (assess renal function before initiation and periodically; contraindicated if e GFR <30 m L/min/1.73 m²),Vitamin B12 deficiency (monitor levels with long-term metformin use),Hypersensitivity reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome),Heart failure (monitor for signs; cardiovascular outcome trials showed no increased risk with saxagliptin, but caution with DPP-4 inhibitors)
Respiratory depression: especially in patients with compromised respiratory function or when used with other CNS depressants,Dependence and abuse liability: Schedule IV controlled substance,Increases in intracranial pressure: may exacerbate in patients with head injury,Cardiovascular effects: may increase cardiac workload and should be avoided in acute MI,Biliary tract spasm: may cause spasm of the sphincter of Oddi,Withdrawal: may precipitate withdrawal in opioid-dependent patients if given shortly after other mu-agonists
Severe renal impairment (e GFR <30 m L/min/1.73 m²),Acute or chronic metabolic acidosis (including diabetic ketoacidosis),History of serious hypersensitivity reaction to Janumet or its components,Use of iodinated contrast agents with e GFR <60 m L/min/1.73 m² or liver disease, alcohol abuse, or conditions altering renal function
Hypersensitivity to butorphanol tartrate or any component of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Known or suspected gastrointestinal obstruction,Patients who are physically dependent on mu-agonists due to risk of acute withdrawal
Avoid excessive alcohol intake (increases risk of lactic acidosis). Take with food to minimize gastrointestinal upset. No specific food restrictions; maintain consistent carbohydrate intake for blood glucose control.
Avoid alcohol and grapefruit juice (may increase butorphanol levels). No specific food restrictions.
Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there are no adequate well-controlled studies in pregnant women. Risk cannot be ruled out. Metformin crosses the placenta and may cause fetal lactic acidosis in third trimester. Generally, insulin is preferred for gestational diabetes management.
Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis produced increased fetal resorptions and decreased fetal weights at doses 3-6 times the human therapeutic dose. In the first trimester, risks cannot be ruled out. In the second and third trimesters, prolonged use may cause neonatal opioid withdrawal syndrome. Use near term may cause respiratory depression in the neonate.
Sitagliptin is excreted in rat milk; unknown in humans. Metformin is excreted into human milk at low levels with an estimated infant dose of 0.18-0.4 mg/kg/day (M/P ratio ~0.35-0.65). Due to potential for hypoglycemia and uncertain long-term effects, breastfeeding is not recommended during Janumet therapy.
Butorphanol is excreted into human milk. The milk-to-plasma ratio (M/P) is approximately 0.7. Limited data suggest low levels; however, due to potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends avoiding use while breastfeeding.
Janumet is not recommended during pregnancy. If used, dose adjustments may be necessary due to pregnancy-induced increased renal clearance of metformin; however, no specific guidelines exist. Renal function should be monitored closely to avoid metformin accumulation and lactic acidosis. Typically, insulin therapy is initiated.
Pregnancy may alter butorphanol pharmacokinetics due to increased plasma volume and enhanced clearance. However, specific dose adjustment recommendations are not established. Use lowest effective dose for shortest duration. For labor analgesia, standard IV/IM doses (1-2 mg) may be used, but monitor for maternal and neonatal respiratory depression.
Janumet combines sitagliptin (DPP-4 inhibitor) and metformin (biguanide). Dose adjustment required for renal impairment (e GFR <45 m L/min/1.73 m² contraindicated; <30 for metformin component). Monitor for lactic acidosis (rare but serious) especially in hypoxic states. Discontinue for 48 hours before iodinated contrast imaging with metformin component. Pancreatitis risk: monitor for persistent severe abdominal pain. Not for type 1 diabetes or ketoacidosis.
Butorphanol is a mixed agonist-antagonist opioid; may precipitate withdrawal in opioid-dependent patients. Ceiling effect on respiratory depression. Higher risk of psychotomimetic effects (dysphoria, hallucinations) compared to morphine. Onset: 1-2 min IV, 5-10 min IM; duration 3-4 hours. Nasal spray has bioavailability ~70%.
Take with meals to reduce gastrointestinal side effects.,If you miss a dose, take it with your next meal unless the next dose is due; do not double dose.,Monitor for symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) and report immediately.,Report symptoms of lactic acidosis (muscle pain, weakness, difficulty breathing, drowsiness) especially if you have kidney problems or are over 65.,Avoid alcohol while taking this medication to reduce the risk of lactic acidosis.,Stay hydrated, especially if you are sick (vomiting, diarrhea) or exercising intensely.,Check blood sugar regularly as directed; carry a source of sugar for hypoglycemia.,Tell your doctor if you are pregnant, breastfeeding, or planning surgery.
May cause drowsiness or dizziness; avoid driving or operating machinery.,Do not take with alcohol or other CNS depressants.,Can cause nausea, vomiting, or sweating; report severe reactions.,Use exactly as prescribed; risk of dependence with long-term use.,If you are dependent on opioids, this drug may cause withdrawal symptoms.,Notify your doctor if you have a history of head injury, asthma, or liver/kidney disease.
No interactions on record
"Butorphanol, a mixed agonist-antagonist opioid, and dimenhydrinate, a histamine H1 antagonist, exhibit additive central nervous system (CNS) depression. Concurrent use increases the risk of profound sedation, respiratory depression, dizziness, and psychomotor impairment. These effects are dose-dependent and can lead to hazardous outcomes such as falls, respiratory compromise, or coma, particularly in elderly or debilitated patients."
"Concomitant use of butorphanol, a mixed agonist-antagonist opioid, with pipotiazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression, including sedation, respiratory depression, and hypotension. Pipotiazine may also potentiate the analgesic effects of butorphanol through antagonism at dopamine D2 receptors, but this combination increases the risk of extrapyramidal symptoms and neuroleptic malignant syndrome. Clinically, patients may experience excessive sedation, confusion, orthostatic hypotension, and impaired psychomotor function."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JANUMET vs BUTORPHANOL TARTRATE, answered by our medical review team.
JANUMET is a DPP-4 Inhibitor/Biguanide Combination that works by Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.. BUTORPHANOL TARTRATE is a Opioid Analgesic that works by Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JANUMET and BUTORPHANOL TARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JANUMET is: Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.. The standard adult dose of BUTORPHANOL TARTRATE is: 1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JANUMET and BUTORPHANOL TARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JANUMET is classified as Category C. Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there. BUTORPHANOL TARTRATE is classified as Category C. Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.